Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Int J Mol Sci
2021 Jan 08;222:. doi: 10.3390/ijms22020593.
Show Gene links
Show Anatomy links
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A
,
Ramlau R
,
Stencel K
.
???displayArticle.abstract???
Lung cancer is one of the most common malignant neoplasms. As a result of the disease's progression, patients may develop metastases to the central nervous system. The prognosis in this location is unfavorable; untreated metastatic lesions may lead to death within one to two months. Existing therapies-neurosurgery and radiation therapy-do not improve the prognosis for every patient. The discovery of Epidermal Growth Factor Receptor (EGFR)-activating mutations and Anaplastic Lymphoma Kinase (ALK) rearrangements in patients with non-small cell lung adenocarcinoma has allowed for the introduction of small-molecule tyrosine kinase inhibitors to the treatment of advanced-stage patients. The Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein with tyrosine kinase-dependent activity. EGFR is present in membranes of all epithelial cells. In physiological conditions, it plays an important role in the process of cell growth and proliferation. Binding the ligand to the EGFR causes its dimerization and the activation of the intracellular signaling cascade. Signal transduction involves the activation of MAPK, AKT, and JNK, resulting in DNA synthesis and cell proliferation. In cancer cells, binding the ligand to the EGFR also leads to its dimerization and transduction of the signal to the cell interior. It has been demonstrated that activating mutations in the gene for EGFR-exon19 (deletion), L858R point mutation in exon 21, and mutation in exon 20 results in cancer cell proliferation. Continuous stimulation of the receptor inhibits apoptosis, stimulates invasion, intensifies angiogenesis, and facilitates the formation of distant metastases. As a consequence, the cancer progresses. These activating gene mutations for the EGFR are present in 10-20% of lung adenocarcinomas. Approximately 3-7% of patients with lung adenocarcinoma have the echinoderm microtubule-associated protein-like 4 (EML4)/ALK fusion gene. The fusion of the two genes EML4 and ALK results in a fusion gene that activates the intracellular signaling pathway, stimulates the proliferation of tumor cells, and inhibits apoptosis. A new group of drugs-small-molecule tyrosine kinase inhibitors-has been developed; the first generation includes gefitinib and erlotinib and the ALK inhibitor crizotinib. These drugs reversibly block the EGFR by stopping the signal transmission to the cell. The second-generation tyrosine kinase inhibitor (TKI) afatinib or ALK inhibitor alectinib block the receptor irreversibly. Clinical trials with TKI in patients with non-small cell lung adenocarcinoma with central nervous system (CNS) metastases have shown prolonged, progression-free survival, a high percentage of objective responses, and improved quality of life. Resistance to treatment with this group of drugs emerging during TKI therapy is the basis for the detection of resistance mutations. The T790M mutation, present in exon 20 of the EGFR gene, is detected in patients treated with first- and second-generation TKI and is overcome by Osimertinib, a third-generation TKI. The I117N resistance mutation in patients with the ALK mutation treated with alectinib is overcome by ceritinib. In this way, sequential therapy ensures the continuity of treatment. In patients with CNS metastases, attempts are made to simultaneously administer radiation therapy and tyrosine kinase inhibitors. Patients with lung adenocarcinoma with CNS metastases, without activating EGFR mutation and without ALK rearrangement, benefit from immunotherapy. This therapeutic option blocks the PD-1 receptor on the surface of T or B lymphocytes or PD-L1 located on cancer cells with an applicable antibody. Based on clinical trials, pembrolizumab and all antibodies are included in the treatment of non-small cell lung carcinoma with CNS metastases.
Figure 3. (A,B) Clustering of mutations in the Epidermal Growth Factor Receptor (EGFR) gene (adapted from Lynch T.J. et al., The New England Journal of Medicine, 2004) [23].
Figure 4. Distribution of the oncogenic driver mutations in non-small cell lung carcinoma (NSCLC) (adapted from Skoulidis F et al., 2019). (A) Early stage and (B) metastatic disease.
Figure 6. Overall response rates and disease control rates obtained with first-line afatinib in the noninterventional GIDEON study [59] (adapted from Brueckl et al., ESMO, 2018).
Ahn,
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
2020, Pubmed
Ahn,
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
2020,
Pubmed
Andrews,
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
2004,
Pubmed
Barrows,
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer.
2019,
Pubmed
Blackhall,
Crizotinib: from discovery to accelerated development to front-line treatment.
2016,
Pubmed
Borghaei,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
2015,
Pubmed
CHASON,
Metastatic carcinoma in the central nervous system and dorsal root ganglia. A prospective autopsy study.
1963,
Pubmed
Cagney,
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.
2017,
Pubmed
Camidge,
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
2019,
Pubmed
,
Echinobase
Camidge,
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
2018,
Pubmed
Carlisle,
Improving outcomes for brain metastases in EGFR mutated NSCLC.
2019,
Pubmed
Castellanos,
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.
2017,
Pubmed
Chen,
Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas.
2019,
Pubmed
Chen,
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
2017,
Pubmed
Chong,
The quest to overcome resistance to EGFR-targeted therapies in cancer.
2013,
Pubmed
Clarke,
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
2010,
Pubmed
Crinò,
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
2019,
Pubmed
Cross,
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
2014,
Pubmed
Fassunke,
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.
2018,
Pubmed
Goss,
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
2016,
Pubmed
Gray,
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
2019,
Pubmed
Grommes,
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
2011,
Pubmed
Haaland,
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
2014,
Pubmed
Han,
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
2012,
Pubmed
Heon,
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
2010,
Pubmed
Herbst,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
2016,
Pubmed
Hirashima,
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
2019,
Pubmed
Hirsch,
Lung cancer: current therapies and new targeted treatments.
2017,
Pubmed
Inoue,
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
2013,
Pubmed
Jackman,
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
2010,
Pubmed
Jang,
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.
2018,
Pubmed
Jiang,
EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
2016,
Pubmed
Jänne,
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
2015,
Pubmed
Karachaliou,
Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
2019,
Pubmed
Keppel,
Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine Kinases.
2017,
Pubmed
Kim,
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
2016,
Pubmed
Kim,
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
2017,
Pubmed
Kosaka,
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
2017,
Pubmed
Kotecha,
Recent advances in managing brain metastasis.
2018,
Pubmed
Lemjabbar-Alaoui,
Lung cancer: Biology and treatment options.
2015,
Pubmed
Leonetti,
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
2019,
Pubmed
Levy,
Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.
2018,
Pubmed
Lim,
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer.
2015,
Pubmed
Lin,
Targeting ALK: Precision Medicine Takes on Drug Resistance.
2017,
Pubmed
Lin,
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
2018,
Pubmed
Liu,
Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer.
2017,
Pubmed
Lowery,
Brain metastasis: Unique challenges and open opportunities.
2017,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Maemondo,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
2010,
Pubmed
Martínez,
Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases.
2017,
Pubmed
Masuda,
Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
2019,
Pubmed
Metro,
CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment.
2015,
Pubmed
Miller,
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
2012,
Pubmed
Mok,
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
2017,
Pubmed
Muliaditan,
Macrophages are exploited from an innate wound healing response to facilitate cancer metastasis.
2018,
Pubmed
Nguyen,
Brain metastases.
2007,
Pubmed
Nishio,
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
2018,
Pubmed
Novello,
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
2016,
Pubmed
Novello,
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
2018,
Pubmed
Noé,
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.
2020,
Pubmed
Nussbaum,
Brain metastases. Histology, multiplicity, surgery, and survival.
1996,
Pubmed
Odogwu,
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
2018,
Pubmed
Ohe,
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
2019,
Pubmed
Okada,
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
2019,
Pubmed
Ou,
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
2014,
Pubmed
Park,
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
2016,
Pubmed
Patil,
Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.
2017,
Pubmed
Planchard,
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.
2016,
Pubmed
Reck,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
2016,
Pubmed
Robinet,
Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1.
2001,
Pubmed
Sahgal,
Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis.
2015,
Pubmed
Sakai,
Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR.
2017,
Pubmed
Schuler,
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
2016,
Pubmed
Sequist,
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
2013,
Pubmed
Shaw,
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
2016,
Pubmed
Shaw,
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
2019,
Pubmed
Shaw,
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
2017,
Pubmed
Sigismund,
Emerging functions of the EGFR in cancer.
2018,
Pubmed
Skoulidis,
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.
2019,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Solomon,
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
2016,
Pubmed
Solomon,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
2014,
Pubmed
Solomon,
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
2018,
Pubmed
Soon,
Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases.
2014,
Pubmed
Sooro,
Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy.
2018,
Pubmed
Soria,
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
2018,
Pubmed
Soria,
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
2017,
Pubmed
Sperduto,
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.
2012,
Pubmed
Sperduto,
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
2017,
Pubmed
Tanaka,
Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation.
2018,
Pubmed
Thomas,
Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors.
2019,
Pubmed
Togashi,
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
2011,
Pubmed
Tomasini,
Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
2019,
Pubmed
Tsao,
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
2012,
Pubmed
Vecht,
Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day.
1994,
Pubmed
Wang,
Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis.
2018,
Pubmed
Wrona,
Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
2018,
Pubmed
Wu,
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
2014,
Pubmed
Yamamoto,
Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.
2014,
Pubmed
Yang,
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
2015,
Pubmed
Yang,
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
2016,
Pubmed
Yang,
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
2015,
Pubmed
Yang,
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
2017,
Pubmed
You,
Immune Microenvironment of Brain Metastases-Are Microglia and Other Brain Macrophages Little Helpers?
2019,
Pubmed
Zhou,
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
2015,
Pubmed
Zimm,
Intracerebral metastases in solid-tumor patients: natural history and results of treatment.
1981,
Pubmed
Zou,
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
2015,
Pubmed